Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 20Unknown 5Terminated 4Withdrawn 2Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Peritoneal Diseases 1

Interventions

Gemcitabine 27Taxes 9Capecitabine 8Albumin-Bound Paclitaxel 6pembrolizumab 5Radiosurgery 5Oxaliplatin 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Specimen Handling 4Secretin 4Fluorouracil 4Drug Therapy 4Ascorbic Acid 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Cyclophosphamide 3Cisplatin 3Biopsy 3palbociclib 2methylnaltrexone 2folfirinox 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Neoplasms × Pancreaticoduodenectomy × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

NCT03718650 2021-02-08

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡